Hormone Replacement Therapy (Female)
Restoration of estrogen, progesterone, and sometimes testosterone in peri/postmenopausal women to alleviate symptoms and support long-term health.
Evidence Summary
Menopausal hormone therapy (MHT) has been substantially reappraised since the early-2000s Women's Health Initiative (WHI) scare. In the WHI's 18-year cumulative follow-up (Manson et al., JAMA 2017; 27,347 women), all-cause mortality for pooled estrogen±progestin therapy trended lower when therapy was started earlier in life — hazard ratio 0.89 (95% CI 0.79–1.01) for women who began at age 50–59, versus 0.98 (0.91–1.05) at 60–69 and 1.03 (0.96–1.10) at 70–79 — although this age trend did not reach statistical significance (P=0.06). This pattern underpins the widely accepted 'timing hypothesis': benefits are most favorable, and risks lowest, when MHT is initiated before age 60 or within 10 years of menopause. A Cochrane systematic review (Boardman et al., 2015) similarly found lower all-cause mortality in this early-initiation group (relative risk 0.70, 95% CI 0.52–0.95). For symptom control the evidence is unambiguous: systemic estrogen is the most effective treatment for moderate-to-severe vasomotor symptoms, and MHT reduces hip and vertebral fracture risk (WHI hip-fracture hazard ratio ≈0.66 for estrogen+progestin). Breast-cancer signals differ by regimen: estrogen-plus-progestin showed a modest long-term increase in invasive breast cancer (hazard ratio ≈1.28), whereas estrogen-alone (in women with prior hysterectomy) was associated with a lower incidence (hazard ratio ≈0.78) — an important distinction for individualized counseling. Reflecting this reappraisal, in November 2025 the U.S. FDA removed the decades-old boxed ('black box') warning from systemic menopausal hormone therapy products, and 2025 guidance from the International Menopause Society and the European Society of Endocrinology reaffirms MHT as first-line therapy for vasomotor symptoms and for bone protection in appropriately selected women. Therapy should remain individualized to each woman's symptoms, age, time since menopause, and personal risk profile. This is educational information, not medical advice.
Evidence Scale
Mechanism of Action
Replaces declining ovarian hormones. Estrogen supports vasomotor function, bone density, cardiovascular health, and cognition. Progesterone balances estrogen and supports sleep.
Who Is This For?
Symptomatic menopause, early menopause, surgical menopause, osteoporosis prevention. Must weigh individual risk factors.
Protocol & Dosing
Dose
Estradiol 0.5-2mg transdermal, Progesterone 100-200mg oral at bedtime. Testosterone 0.5-2mg as needed.
Frequency
Daily
Duration
Ongoing with annual reassessment
Protocol Summary
Bioidentical estradiol + progesterone preferred. Various routes: transdermal, oral, vaginal. Individualized dosing.
Human RCT Follow-up · WHI 18-year
All-cause mortality by age at initiation: the timing hypothesis
Pooled estrogen±progestin therapy vs placebo; hazard ratios below 1.0 favor therapy. The gradient toward lower mortality with earlier initiation supports the 'timing hypothesis', though the age trend was not statistically significant (P=0.06). Source: Women's Health Initiative 18-year cumulative follow-up, Manson et al., JAMA 2017;318(10):927–938.
Latest Evidence
The modern reappraisal of menopausal hormone therapy centers on timing: initiated before age 60 or within 10 years of menopause, MHT is the most effective treatment for vasomotor symptoms and supports bone health, with a reassuring long-term profile. In November 2025 the FDA removed the decades-old boxed warning from systemic MHT products.
Interactions & Precautions
Contraindications
- Breast cancer history
- Active thromboembolism
- Unexplained vaginal bleeding
- Active liver disease
Potential Risks
- •Breast cancer risk (debated)
- •Thromboembolism
- •Gallbladder disease
Potential Side Effects
Practitioner Notes
Clinical annotations from Dr. Goel
Transdermal estradiol avoids first-pass liver effects. Start within 10 years of menopause for best outcomes. Oral micronized progesterone for endometrial protection. Updated August 16, 2026 (context, not a change in recommendation): Nature Aging 2026 (Carleton et al.) profiled age-associated differences in ER-positive breast cancer using an aged rat model, human patient tissue and patient-derived organoids, and found that systemic and local chronic inflammation together with altered ENDOGENOUS estrogen disposition create a tumour-permissive breast microenvironment in older women. Read this carefully before it reaches patients in distorted form: the study concerns host aging biology and endogenous hormone metabolism, it tested no exogenous hormone therapy, and it says nothing about whether menopausal hormone therapy raises or lowers this risk. It does not alter HRT risk-benefit counselling, which should continue to rest on the randomised and observational literature already summarised above. Its practical value is as a reminder that inflammatory and metabolic status in older women is part of the breast-cancer risk conversation independent of hormone exposure. Updated October 15, 2026: In November 2025 the U.S. FDA removed the long-standing boxed warning from systemic menopausal hormone therapy products. Counsel on the timing hypothesis (best initiated before age 60 or within 10 years of menopause) and on regimen-specific breast-cancer considerations (estrogen-plus-progestin vs estrogen-alone). Prefer transdermal estradiol to reduce venous thromboembolism risk; ensure endometrial protection with progestogen in women with a uterus.
Dr. Sanjeev Goel
Chief Medical Officer, Peak Human
Cost & Access
Cost Range
$$
Accessibility
Availability varies by location
Sample member
Longevity Operator
One number for your longevity journey.
FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.
- Metabolic
- Hormonal
- Cardiovascular
- Brain / Cognitive
- Sleep
- Musculoskeletal
- Gut
- Immunity / Inflammation
